Abstract The involvement of the immune system for the course of breast cancer, as evidenced by varying degrees of lymphocyte infiltration (LI) into the tumor is still poorly understood. The aim of this study was to evaluate the prognostic value of LI in breast cancer samples using microarray-based screening for LI-associated genes. Starting from the observation that most published ER gene signatures are heavily influenced by the LI effect, we developed and applied a novel approach to dissect molecular signatures. Further, a meta-analysis encompassing 1,044 hybridizations showed that LI alone is not sufficient to highlight breast cancer patients with different prognosis. However, for ER positive patients, high LI was associated with shorter survival times, whereas for ER negative patients, high LI is significantly associated with longer survival. Annotation of LI, in addition to ER status, is important for breast cancer patient prognosis and may have implications for the future treatment of breast cancer.
Introduction
Breast cancer is the most frequent cancer in women in western countries [14] . The most common breast cancer subtype, the invasive ductal carcinoma (IDC), represents more than 75% of all cases and is not further sub-classified with currently established methods. Many reports on the molecular classification of breast cancer entities are available. Some of these studies attempted to predict patient survival [36, 40] . Others found different molecular subclasses to be associated with clinical parameters like lymph node status or grading [36, 42] . However, only one of the identified prognosis signatures has so far entered the clinical practice [13] . Effective methods to stratify patients for different therapeutic regimens, and consecutively to estimate individual outcome, are still urgently needed. Malignant human tumors are often accompanied by the infiltration of immune cells into the region of tumor cell proliferation. Various publications [6, 21, 27, 31, 33] reported the effects of lymphocyte infiltration (LI) in human solid tumors. However, the prognostic significance of LI in cancer remains controversial. LI was described to be beneficial for patient outcome in certain publications [32] , and detrimental in others [15, 17, 18, 23] . In breast cancer the use of this parameter as a prognostic factor remains a matter of debate [2, 7, 22, 29] . The main reason for this can be attributed to the intrinsic difficulty in separating confounding factors in the analysis: LI is more pronounced in ER negative than in ER positive tumors [38, 43, 44] . Consequently, every breast cancer screening study focusing on LI and patient survival will see its outcome greatly affected by the well-known role of the ER. A second reason for the difficulties in assigning a role to LI for patient survival may be due to the fact that, in contrast to the ER status, the occurrence of LI is not routinely assessed in histopathological reports and consequently, data for comparative studies are often lacking. To overcome these limitations, we developed a microarray-based approach to estimate the presence of LI. We used this estimator for LI to computationally microdissect the gene signatures that distinguish the ER positive and ER negative tumors, and we applied it to a novel microarray dataset encompassing 155 breast cancer samples. We suggest that these signatures reflect more accurately the biological processes which play a role in breast cancer progression. Furthermore, in an individual patient data IPD meta-analysis with altogether 1,044 patient samples from five publicly available breast cancer microarray datasets [10, 30, 36, 37, 41] as well as our own dataset, we found that LI has contrasting effects on the survival of patients suffering from breast cancer, depending on whether ER is expressed or not.
Materials and methods

Sample preparation
155 cryo-preserved human primary breast tumor samples which had been surgically resected between the years 1990 and 1992 were retrieved from the biobank of the Medical University of Graz [5] . Before enrollment into the microarray experiments, the tissue samples underwent a careful re-analysis of the histopathology by two independent pathologists. The sample annotation (Table 1) included patients age at time of surgery (mean = 59 years), estrogen receptor status (negative, n = 61; positive, n = 94), lymphocyte infiltration (negative, n = 18; positive, n = 27) and overall survival time. The study has been approved by the Ethical Committee of the Medical University of Graz. Total cellular RNA was isolated from slices of tissue stored in RNAlater (Qiagen, Hilden, Germany) at -80°C using an RNeasy Mini kit (Qiagen) after homogenization with a Mikro-Dismembrator S (Braun Biotech, Melsungen, Germany). The quality of RNA was verified with the Agilent 2100 bioanalyzer (Agilent Technologies, Waldbronn, Germany). Only high-quality RNA samples (28S:18S ribosomal RNA ratio [ 1.8) were selected for oligonucleotide microarray hybridization. Amplification, cDNA synthesis and labeling were performed using the TacKle protocol [34] .
Microarray processing
The microarrays carried the Human oligonucleotide set V4.0 (Operon technologies, Cologne, Germany), which consists of 35,035 oligonucleotides (average length: 70 bases) representing 33,791 transcripts of the Ensembl human build NCBI-35c, and 28,902 of Refseq. The oligonucleotides were spotted using the VersArray ChipWriter Pro (Bio-Rad, Munich, Germany) and SMP3 pins (Telechem, Sunnyvale, CA) onto epoxysilane-coated glass slides (Nexterion slide E, Schott, Mainz, Germany). Afterwards, microarrays were rehydrated, and the DNA was denatured with boiling water prior to washing with 0.2% sodium dodecyl sulfate, water, ethanol, and isopropanol. The arrays were dried with air pressure.
Microarray hybridization and data analysis
Amplified tumor-derived RNA was labeled with Cy5, and amplified common reference RNA (Stratagene, La Jolla, [12] . The limma (version 2.12) software package [35] was used to identify differentially expressed genes. All data analyses were performed using the R (version 2.6) statistical computing environment [1] . The entire dataset is available at GEO [20] under the ID: GSE10510.
Computational microdissection based on quantitative markers
A linear model was applied to test for significant effects of ER status and LI on gene expression, when analyzing microarray data obtained from patient material. First, the microarray data were transformed to log2 values and quantile-normalized. We used an indicator variable [0,1] to distinguish ER negative and ER positive patients and continuous variables based on the gene expression of marker genes to quantify the presence of LI. Next, we fitted a linear model for each gene, which modeled gene expression measurement according to ER status, LI effect and their potential interaction. The P-value for each explanatory factor was computed by using moderated t-statstics, including empirical Bayes estimation of the residual standard deviation [35] . P-values were adjusted for multiple testing controlling the false-discovery-rate (FDR) as defined by Benjamini and Hochberg [24] . All calculations were performed using the R limma package. The marker genes for LI were annotated in Suppl. Table A according to the REMARK criteria [28] .
Analysis of significant biological function represented in a gene list
Functional gene categories were identified with the assistance of the Ingenuity pathway analysis (IPA) version 5.5.1 (Ingenuity Systems, Mountain View, CA. https://analysis. ingenuity.com). IPA's functional analysis compares the data across different biological functions and produces a scored list. The classes defined as ''Immune and Lymphatic System Development and Function'', ''Immunological Disease'' and ''Immune Response'' were used to deplete the ER gene list from the genes related to LI. Enrichment of gene ontology (GO) classes was computed based on contingency tables from either of the three gene lists of interest and from the complete array and tested using Fisher 0 s exact tests [8] .
Prediction of patient survival
Survival analysis was performed using merged data from the different platforms. ER status was based on the pathologists' annotation, which was available for all 1,044 patients. Presence and intensity of LI were predicted based on the gene expression signatures of marker genes from the microarray studies. The primary analysis was done to test the effects and significance of LI and ER status on patient survival by fitting a Cox proportional hazards regression model including an interaction factor to test for possible interactive effects of ER and LI [16] . A stratification factor for each platform was included in the model to account for the different data sources. To provide quantitative information on the relevance of results, 95% confidence intervals of hazard ratios (HR) were computed. For LI hazard ratio estimates were computed for a change from lower to upper quartile of computed LI intensities. Stratified Cox models were fitted using ER only, the LI only and the LI in the ER negative and ER positive patients separately, as well as in the subset defined by IDC. The method of Kaplan and Meier was used to estimate survival time distributions. For illustration purposes, the continuous LI variable was dichotomized to build two groups at a ratio of 1:2 (reflecting the ER-/ER+ ratio in the population). Kaplan-Meier plots were drawn for the subgroups defined by ER and dichotomized LI (Fig. 2) . All analyses were performed using the R packages survival (version 2.32) and design (version 2.1). The IDC patient subset was generated by selecting the samples annotated as IDC in Sorlie et al. [36] and in our own platforms, the only two datasets which included such information.
Publicly available datasets for an IPD meta-analysis Public datasets were obtained from the GEO database [20] . The criteria for the selection of the publicly available dataset were: the presence of annotation for overall survival and the presence of a record for ER status. Hybridizations present in more than one study were counted only once in the survival analysis. Only samples annotated as IDC in the original paper were considered for the IDC only analysis. The information related to the publicly available datasets used for the IPD meta-analysis is summarized in Table 1 . The van't Veer dataset (3) was not included in the IPD meta-analysis as the samples are largely overlapping with the dataset of van de Vijver [41] .
Results
Determination of LI through gene expression studies based on marker genes
In order to compute an intensity score for lymphocyte infiltration (LI), we selected known lymphocyte-specific marker genes from the literature, including the genes coding for cell surface proteins, immunoglobulin genes, and others. These genes were evaluated for their transcriptional activity using tissue specific EST expression databases (SAGEmap [26] ; SÁO.U.R.C.E. [19] ). The eighteen following specific lymphocyte marker genes (CCL5, CD19, CD37, CD3D, CD3E, CD3G, CD3Z, CD79A, CD79B, CD8A, CD8B1, IGHG3, IGJ, IGLC1, CD14, LCK, LTB, MS4A1; Suppl. Table A, Suppl. Fig. D) were then tested on the expression data of our own microarray platform. In order to use these as quantitative markers in the linear model analysis of cell mixtures and in the survival analysis, the gene expression profiles of each of the features corresponding to these genes were standardized to have mean zero and unit variance. To remove low quality features, spots with fold changes smaller than 1.5 were excluded. Subsequently, for each patient the mean of all remaining standardized features was used as a score for the presence of LI. To validate the performance of this method, we mapped the LI marker genes onto data from an independent array platform and compared the outcome to the LI information. To this end, we selected the dataset by van't Veer [40] and Bertucci [9] , which are among the few breast cancer microarray datasets in which the LI annotation based on histopathological characterization of the tissues is provided. We observed significantly positive correlation coefficients between the pathological annotation data and the continuous parameter that we computed based on the molecular markers in both these platforms. 
Computational microdissection of ER and LI effects
In order to understand the effects of ER expression in breast cancer cells, it is common practice to perform gene expression studies and compute the gene signatures that distinguish ER positive from ER negative patients. However, the published signatures are, however, heavily influenced by the LI effect and are of limited use for functional interpretations, as they include a large fraction of the genes that are expressed in immune cells [38] . In the van't Veer dataset, 538 out of 2,556 features are annotated as lymphocyte related (20.8%). Similarly in our platform these numbers are 599 out of 2,160 (27.7%). In order to distinguish the different effects, we developed a method to computationally microdissect the gene expression signatures from the various cell types in these complex tissues and applied it to our dataset of 155 breast cancer samples. The linear regression analysis comparing patients with different ER status according to histopathology resulted in 2,160 differentially expressed features (FDR \ 0.05), 936 of which were functionally annotated (Suppl. Table C ). The analysis of this gene list (''ER basic'') revealed a large portion of genes involved in ''immune response'' and ''activation of leukocytes'' that were significantly associated with ER status (Fig. 1) . Therefore, we applied our computational microdissection method in order to eliminate the transcriptional variation generated from the infiltrating lymphocytes. The resulting ''ER microdissected'' gene list analysis revealed only 629 genes associated with ER expression. Of these, 284 were fully annotated with functional categories ''DNA replication and repair'', ''cancer'' and ''reproductive system disease'' being the most significant ones. In order to evaluate the result of our new method, we performed a third analysis in which we deprived the ''ER basic'' of all genes with a GO annotation related to expression in lymphocytes. This gene list that we identify as ''ER filtered'' represents an alternative approach to remove lymphocyte related genes present in the ER positive versus ER negative comparison. The ''ER filtered'' list consisted of 337 genes, which were sorted according to known gene functions. The genes filtered in this process belonged to functions mainly characteristic for immune cells but among them we also found genes which might be expressed in breast epithelial cell. This is not surprising as the GO annotation may represent several different functions of a gene and therefore has the intrinsic limitation in assigning a gene univocally to a biological function in a specific condition. For example, the ER gene itself that was filtered as related with LI. Figure 1 compares these three different methods at the GO level: the ''ER basic'', the ''ER filtered'' and the ''ER microdissected'' gene lists. While the most significant terms in the ''ER gene list'' were associated with immune processes, the analysis of the ''ER microdissected'' list did not show any significant lymphocyte elements. In summary, the microdissection method helped to remove the GO classes related with lymphocytes and the resulting gene list became more focused on the biological processes relevant to tumor cells. We performed similar analyses with the other publicly available datasets (Table 1 ). The genes in each analysis show a high degree of consistency with the list based on our dataset. Consistency was higher in the ''ER microdissected'' than in the ''ER basic'' (Suppl. Table B) .
Survival analysis based on ER and LI marker genes
To quantitatively evaluate the effect of LI as a parameter indicative for the prognosis of breast cancer patients, we used the previously selected marker genes to evaluate quantitatively the presence of LI in the original tissue samples. The molecular markers indicated their general suitability for the analysis of complex tissues microarray data. We mapped the marker genes to published datasets, which were selected depending on the availability of data on ER and overall survival (OS) of patients. For this purpose, we included data from six microarray studies (Table 1) . These six datasets included 1,044 hybridizations with primary breast cancer samples. In the following, we used the immunohistochemistry based on the pathologist's annotations for ER status and our quantitative estimate for the LI for survival analysis. The prognostic value of ER expression and LI was evaluated in nested analyses. The presence or absence of LI alone did not reveal a significant impact on OS (stratified Cox regression P = 0.12; Fig. 2a) . However, as expected, patients with ER positive tumors had a significantly better prognosis when compared to patients with ER negative tumors (stratified Cox regression: P-value \ 0.001; Fig. 2b ). LI was not significantly associated with therapy in the two datasets that were amenable for this analysis (Sotiriou et al. [37] and our own; data not shown).
In an attempt to test for interactive effects of LI and ER, we used a stratified Cox model with interaction factor. We identified a statistically significant interaction between ER and LI (Table 2 ; Fig. 2c ). In this analysis, patients with an increased LI level showed a slightly worse prognosis in the ER positive patients. In the ER positive patients the estimated hazard ratio (HR), when comparing patients at the 75% percentile and at the 25% percentiles of LI, was 1.15 with a 95% confidence interval CI = 0.94-1.40. In value when the biological classes used for the depletion step are considered. ''Not present'' means no value has been assigned to that biological function contrast, ER negative patients with high LI levels show a dramatically better prognosis than ER negative patients with low LI levels (HR = 0.67, CI = 0.53-0.86). To further investigate the difference in survival, we reduced the influence of possible confounding factors due to histopathological heterogeneity. To account for this, we restricted the analysis to the invasive ductal breast carcinomas (IDC) only and performed a similar analysis as described before. Only 211 out of 1,044 samples were annotated as IDC in the two out of six different platforms, since no annotation was available for most of the patients. Figure 2d illustrates the result of the analysis limited to the IDC subset. Despite of the drastic reduction of the sample numbers, the results remained comparable to those obtained computing all samples (Table 2) .
Discussion
Breast cancer is highly heterogeneous with respect to clinical and histopathological appearance as well as to patient survival. The involvement of hormonal and growth Hazard ratios and confidence intervals (CIs) for LI are computed for an increment corresponding to the interquartile range (IQR) of LI intensities in reference to ER. Likewise the P-values for ER are based on the Wald statistics for testing the ER effect (ER + LI by ER interaction). Hazard ratios and confidence intervals (CIs) for ER are computed for the ER positive patients vs. the ER negative patients and adjusted for LI intensity factors in breast cancer progression has been known for decades. Consequently, highly effective therapies are available which target the major promoters of breast cancer, i.e. the estrogen and the epidermal growth factor receptors (ESR1 and ERBB2). However, the prediction of breast cancer therapy success and patient benefit is still poorly developed. Improved patient stratification tools are urgently required before novel therapeutic targets can be identified and specific therapies can be devised. Therefore, we developed a method for the in silico microdissection of complex molecular signatures from microarray experiments. It relies on the definition, validation and application of specific genes as representatives for the expression of a much larger number of genes behaving similarly in certain cell types and tissues. We call this approach ''computational microdissection'' of complex gene expression patterns. It allows the a posteriori separation of different cell types in microarray experiments performed on complex tissue samples (e.g. the tumor cells and their microenvironment). Theoretically, the method can be applied to any tumor entity or array platform. The computational microdissection has proved its usefulness as an approach applicable to circumstances where the physical separation of different cell types before molecular analysis is not possible (as for retrospective microarray studies). In addition, it might be a useful knowledge-based tool to distinguish the different contributions of tumor and stromal cells to cancer development and progression. Furthermore, we approached the highly debated relevance of LI as a prognostic marker. Our finding is consistent with recent reports [25, 38, 39] and suggest opposite role of LI in ER positive and negative patients. These studies do in fact highlight that a better prognosis of ER negative patients is associated with lymphocyte related genes in the tumor microenvironment. We aimed to estimate the level of LI by using a small set of lymphocyte specific marker genes that enables us to study the interaction between the important prognostic factors ER status and LI, in independent studies even without LI annotation data. Due to the larger sample size in our analysis, it was possible to show a statistically significant effect of LI on survival in ER negative patients. Our study, based on molecular data of more than 1,000 breast cancer samples from multiple centers, suggests that LI when considered in relation to ER status is significantly associated with patient survival in breast tumors. A major contributing factor to overall survival remains ER expression. Nonetheless we identified significant adverse effects of LI on the overall survival of breast cancer patients with or without ER expression: LI is beneficial for ER negative patients but probably unfavorable for ER positive patients. This is particularly true for the patients belonging to the IDC subset. However, since we used a limited number of B-and T-cell marker genes, it is likely that further gene signatures associated to distinct immune response or tumor-intrinsic characteristics are also present and prognostically relevant.
Our results might reflect intrinsic differences in the biology of breast-tumor subtypes, leading to a difference in tumor immune surveillance depending on the estrogen receptor status. LI occurs as a reaction of the organism to the growing tumor mass and it is known to play a role in generating a signaling microenvironment for the tumor. This stroma might become a source of endocrine factors fostering tumor growth [17] . Recent publications have shown that regulation of the immune system by ER is possible [11] and that the tumor is acting on the signaling microenvironment in order to promote immune tolerance [4] . However, further cellular and molecular analysis is required to unravel the mechanism underlying this hypothesis. Despite these open questions, our results suggest that the acquisition of multiple clinical, histopathological and molecular parameters, combined with IPD meta-analyses of microarray datasets can considerably contribute to breast cancer patient stratification to predict disease outcome. Our results indicate that LI, when combined with ER status, is a relevant prognostic factor for breast cancer. This confirms similar observations of a recent study, reporting the association of LI with HER2-positive breast cancer [3] . We suggest that existing as well as novel specific targets aiming at the treatment of breast cancer patient subgroups should be evaluated in the light of these data.
